| |
NS period
|
H period
|
HS period
|
|---|
|
MAP (mm Hg)
|
94 ± 3
|
84 ± 4a
|
81 ± 4a
|
|
HR (beats per minute)
|
83 ± 6
|
81 ± 5
|
78 ± 5
|
|
CO (litres/minute)
|
5.38 ± 0.82
|
5.27 ± 0.82
|
5.33 ± 1.08
|
|
SpO2 (percentage)
|
96.4 ± 0.5
|
96.7 ± 0.5
|
96.1 ± 0.5
|
|
tcPO2 (mm Hg)
|
67 ± 6
|
61 ± 6
|
61 ± 7
|
|
tcPCO2 (mm Hg)
|
45 ± 2
|
44 ± 4
|
42 ± 4
|
|
Φrest (PU)
|
150 ± 22
|
207 ± 25a
|
205 ± 25a
|
|
CMBC (CU)
|
145 ± 15
|
152 ± 16
|
155 ± 15
|
|
Velocity (VU)
|
1.06 ± 0.11
|
1.39 ± 0.15a
|
1.37 ± 0.79a
|
- ap < 0.05 versus NS period. Φrest, mean blood flow at rest; CMBC, concentration of moving blood cells in concentration units (CU); CO, cardiac output; H period, set of measurements obtained when the patients were sedated by midazolam; HR, heart rate; HS period, set of measurements obtained when the patients were sedated by midazolam and sufentanil; MAP, mean arterial pressure; NS period, set of measurements obtained when the patients were non-sedated; PU, perfusion units; SpO2, percutaneous oxygen saturation; tcPCO2, transcutaneous carbon dioxide pressure; tcPO2, transcutaneous oxygen pressure; velocity expressed in velocity units (VU), Φrest (perfusion units)/CMBC.
